RBC Capital lowered the firm’s price target on Select Medical (SEM) to $19 from $23 but keeps an Outperform rating on the shares. Shares have declined over 20% since the company posted weaker Q1 results last week and modestly lowered its guidance range, primarily due to CIRH margin pressure caused by the high-cost outlier threshold, but while the higher threshold represents a formidable reimbursement headwind, RBC believes lower acuity expected in next few quarters should limit the impact for the balance of the year, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SEM: